First Hawaiian Bank Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL)

First Hawaiian Bank cut its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 57.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,476 shares of the medical research company's stock after selling 6,071 shares during the period. First Hawaiian Bank's holdings in Charles River Laboratories International were worth $826,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $32,000. Assetmark Inc. boosted its position in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after purchasing an additional 173 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Charles River Laboratories International during the 3rd quarter worth approximately $59,000. Finally, Covestor Ltd increased its position in Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after buying an additional 95 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on CRL. TD Cowen increased their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. Citigroup cut shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective on the stock. UBS Group increased their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Finally, Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $214.00.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $1.84 during trading on Friday, hitting $186.07. 911,473 shares of the company were exchanged, compared to its average volume of 626,345. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a market cap of $9.51 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 5.00 and a beta of 1.38. The firm's fifty day moving average price is $193.42 and its 200 day moving average price is $199.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. During the same quarter last year, the business earned $2.72 earnings per share. The business's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).